Roy M. Pollock

11.6k citations

55 papers · 6.4k indexed · 5 hit papers · h-index 29

Hematology top 1%
- Acute Myeloid Leukemia Research 15
- Multiple Myeloma Research and Treatments 5
Molecular Biology top 1%
- Epigenetics and DNA Methylation 23
- Cancer-related gene regulation 21
- Ubiquitin and proteasome pathways 8
- Protein Degradation and Inhibitors 7
- RNA Interference and Gene Delivery 4
- Chromatin Remodeling and Cancer 4
Genetics top 2%
Cancer Research top 5%
Genetics top 5%

Co-authors: Richard Treisman Victoria M. Richon M J Runswick Christine M. Norman Robert A. Copeland Margaret Porter Scott Kevin W. Kuntz Tim Clackson
Cited by: Hematology Molecular Biology Genetics
Journals: Blood (12 papers)Proceedings of the National Academy of Sciences (5 papers)PLoS ONE (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Roy M. Pollock

55 papers receiving 6.1k citations

Hit Papers

5 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2013 Proceedings of the National Academy of Sciences
2013 Blood
2011 Cancer Cell
2010 Proceedings of the National Academy of Sciences
1988 Cell

Peers

Countries citing papers authored by Roy M. Pollock

Since Specialization

Citations

This map shows the geographic impact of Roy M. Pollock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy M. Pollock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy M. Pollock more than expected).

Fields of papers citing papers by Roy M. Pollock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy M. Pollock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy M. Pollock. The network helps show where Roy M. Pollock may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Roy M. Pollock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roy M. Pollock Line = papers co-authored together Roy M. Pollock links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents Hematological Oncology ·Michael J. Thomenius,Fuat Belli,Jason K. Kirby,Roman V. Agafonov,Prasoon Chaturvedi,Scott J. Eron,A. C. Good,John Hart,Miaoling He,Andrew J. K. Phillips,David A. Proia,James A. Henderson,Christopher G. Nasveschuk,Stewart L. Fisher,Roy M. Pollock	2023	4
2	CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents Blood ·義雲服部,Karin Lindkvist,Roman V. Agafonov,Prasoon Chaturvedi,Scott J. Eron,Andrew C. Good,M Komata,Jan-Laurin Mueller,Riadh Lobbardi,Andrew J. Phillips,David A. Proia,James A. Henderson,Marina Filier de Oliveira,Christopher G. Nasveschuk,Stewart L. Fisher,Roy M. Pollock	2022	1
3	Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL -Rearranged Leukemia Molecular Cancer Therapeutics ·Carly Campbell,J.P.Jr. Yap,David A. Drubin,Timothy M. Thomson,倪志安,T P Kennedy,Nigel J. Waters,Edward J. Olhava,Roy M. Pollock,J. Joshua Smith,Robert A. Copeland,Stephen J. Blakemore,Kathrin M. Bernt,Scott R. Daigle	2017	46
4	Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma PLoS ONE ·Satoshi Kawano,Alexandra Grassian,Masumi Tsuda,Sarah K. Knutson,Natalie M. Warholic,Galina Kuznetsov,Shanqin Xu,Yonghong Xiao,Roy M. Pollock,Dewi Kania Intan Permatasari,张叔英,Scott Ribich,Yukinori Minoshima,Junji Matsui,Robert A. Copeland,Shinya Tanaka,Heike Keilhack	2016	58
5	Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human Cancer Chemotherapy and Pharmacology ·Nigel J. Waters,Sherri Smith,Edward J. Olhava,Kenneth W. Duncan,Richard D. E. Burton,Yuvraj Dhobale,M. Firouzbakht,Roy M. Pollock,Mikel P. Moyer,Richard Chesworth	2015	23
6	DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells Journal of Pharmacology and Experimental Therapeutics ·Christine R. Klaus,Yuyun Wahyuningrum,Danielle Johnston,Shijing Fang,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Edward J. Olhava,Margaret Porter Scott,Roy M. Pollock,Scott R. Daigle,Alejandra Raimondi	2014	96
7	Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas PLoS ONE ·Sarah K. Knutson,Natalie M. Warholic,L. Danielle Johnston,Christine R. Klaus,Tim J. Wigle,Yuyun Wahyuningrum,Bruce A. Littlefield,Julia Kuhrau,J. Joshua Smith,Mikel P. Moyer,Robert A. Copeland,Roy M. Pollock,Kevin W. Kuntz,Alejandra Raimondi,Heike Keilhack	2014	55
8	Potent inhibition of DOT1L as treatment of MLL-fusion leukemiabreakdown → Blood ·Scott R. Daigle,Edward J. Olhava,正樹北薗,Aravind Basavapathruni,Lei Jin,P. Ann Boriack‐Sjodin,Christina J. Allain,Christine R. Klaus,Alejandra Raimondi,Margaret Porter Scott,Nigel J. Waters,Richard Chesworth,Mikel P. Moyer,Robert A. Copeland,Victoria M. Richon,Roy M. Pollock	2013	546
9	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L Chemical Biology & Drug Design ·Aravind Basavapathruni,Lei Jin,Scott R. Daigle,Christina R. Majer,正樹北薗,Tim J. Wigle,Kevin W. Kuntz,Richard Chesworth,Roy M. Pollock,Margaret Porter Scott,Mikel P. Moyer,Victoria M. Richon,Robert A. Copeland,Edward J. Olhava	2012	114
10	Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l Leukemia ·Liang Chen,Anagha Deshpande,Deepti Banka,Kathrin M. Bernt,Sérgio Dias,Christian Buske,Edward J. Olhava,Scott R. Daigle,Victoria M. Richon,Roy M. Pollock,Scott A. Armstrong	2012	101
11	Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens Molecular Cancer Therapeutics ·Victor M. Rivera,Rachel M. Squillace,David F. Miller,Lori Berk,Scott Wardwell,Yaoyu Ning,Roy M. Pollock,Narayana I. Narasimhan,John D. Iuliucci,Frank Wang,Tim Clackson	2011	87
12	MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1Lbreakdown → Cancer Cell ·Kathrin M. Bernt,Nan Zhu,Amit Sinha,Sridhar Vempati,Joerg Faber,Andrei V. Krivtsov,Zhaohui Feng,介晓阳,Liu Lvfeng,Lars Bullinger,Roy M. Pollock,Victoria M. Richon,Andrew L. Kung,Scott A. Armstrong	2011	642
13	Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasbreakdown → Proceedings of the National Academy of Sciences ·Christopher J. Sneeringer,Margaret Porter Scott,Kevin W. Kuntz,Sarah K. Knutson,Roy M. Pollock,Victoria M. Richon,Robert A. Copeland	2010	500
14	Dimerizer-regulated gene expression Current Opinion in Biotechnology ·Roy M. Pollock,Tim Clackson	2002	82
15	A Guide to Hematology in Dogs and Cats Alan H. Rebar,Peter S. MacWilliams,Bernard J. Feldman,Martins Ilebvbare,Roy M. Pollock,J.R. Roche	2001	8
16	[15] Regulation of gene expression with synthetic dimerizers Methods in enzymology on CD-ROM/Methods in enzymology ·Roy M. Pollock,Victor M. Rivera	1999	13
17	A humanized system for pharmacologic control of gene expression Nature Medicine ·Victor M. Rivera,Tim Clackson,Sridaran Natesan,Roy M. Pollock,Jane F. Amara,Terence P. Keenan,Shannon R. Magari,T. G. Phillips,Marden Augusto Viana de Morais,Franklin Cerasoli,Dennis A. Holt,Michael Gilman	1996	433
18	A sensitive method for the determination of protein-DNA binding specificities Nucleic Acids Research ·Roy M. Pollock,Richard Treisman	1990	308
19	Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response elementbreakdown → Cell ·Christine M. Norman,M J Runswick,Roy M. Pollock,Richard Treisman	1988	880
20	Identification and purification of EBP1: a HeLa cell protein that binds to a region overlapping the 'core' of the SV40 enhancer. Genes & Development ·Mr. Jainin N. Dave,Roy M. Pollock,Ronald T. Hay	1988	60

About Roy M. Pollock

Roy M. Pollock is a scholar working on Hematology, Molecular Biology, Pathology and Forensic Medicine, Oncology and Genetics, having authored 55 papers that have together received 6.4k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (23 papers), Cancer-related gene regulation (21 papers), Acute Myeloid Leukemia Research (15 papers), Ubiquitin and proteasome pathways (8 papers), Protein Degradation and Inhibitors (7 papers), Multiple Myeloma Research and Treatments (5 papers), RNA Interference and Gene Delivery (4 papers) and Chromatin Remodeling and Cancer (4 papers). The work is most often cited by research in Hematology (958 citations), Molecular Biology (5.4k citations), Genetics (748 citations), Cancer Research (368 citations) and Genetics (250 citations). Roy M. Pollock has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Richard Treisman, Victoria M. Richon, M J Runswick, Christine M. Norman, Robert A. Copeland, Margaret Porter Scott, Kevin W. Kuntz, Tim Clackson, Sarah K. Knutson and Mikel P. Moyer. Their work appears in journals such as Blood, Proceedings of the National Academy of Sciences, PLoS ONE, Molecular Cancer Therapeutics and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact